[Gene therapy for osteoarticular disorders]
| Autor: | Jean-Noël, Gouze, Christopher H, Evans, Steven C, Ghivizzani, Elvire, Gouze |
|---|---|
| Jazyk: | francouzština |
| Rok vydání: | 2007 |
| Předmět: |
Cartilage
Articular Sirolimus DNA Complementary Genetic Vectors Gene Expression Genetic Therapy Haplorhini Dependovirus Middle Aged Receptors Tumor Necrosis Factor Etanercept Injections Intra-Articular Arthritis Rheumatoid Mice Dogs Doxycycline Immunoglobulin G Osteoarthritis Genes Synthetic Animals Cytokines Humans Receptors Tumor Necrosis Factor Type II Horses Aged |
| Zdroj: | Medecine sciences : M/S. 23(3) |
| ISSN: | 0767-0974 |
| Popis: | Osteoarticular disorders are the major cause of disability in Europe and North America. It is estimated that rheumatoid arthritis affects 1 % of the population and that more than two third of people over age 55 develop osteoarthritis. Because there are no satisfactory treatments, gene therapy offers a new therapeutic approach. The delivery of cDNA encoding anti-arthritic proteins to articular cells has shown therapeutic efficacy in numerous animal models in vivo. Through the development and the experimental progresses that have been made for both rheumatoid arthritis and osteoarthritis, this review discusses the different gene therapy strategies available today and the safety issues with which they may be associated. Among the different vectors available today, adeno-associated virus seems the best candidate for a direct in vivo gene delivery approach for the treatment of joint disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|